What is Semaglutide? It’s a longer-lasting copy of a gut hormone.
A 31-amino-acid chain, made from protein parts, stays much longer than your natural GLP-1 hormone.
What Semaglutide copies from your body
Made to act like a gut hormone, semaglutide is a medicine that lasts far longer. This page explains what the copy is and why it stays longer. I’d picture a familiar body message with a much longer life.
Your gut releases the hormone after you eat. It helps control blood sugar and tells your brain that you’re full. The medical name is GLP-1. Semaglutide is a peptide, meaning a short chain of the small parts that make protein.
Your body removes natural GLP-1 in about two minutes. The changed copy keeps working for roughly a week [9]. One form is a weekly shot, while the other is a daily pill. Semaglutide is an approved medicine, not a lab test.
How the Semaglutide peptide stays in your blood
Built from protein parts, semaglutide forms a 31-amino-acid chain. Its order is about 94% the same as GLP-1, your gut hormone. Scientists changed only a few places so your body wouldn’t clear the medicine too soon.
They changed places numbered 8 and 34, then attached a fat-like tail at 26 [9]. An enzyme called DPP-4 acts like a protein-cutting tool in your body. Those small changes shield semaglutide from that tool and leave one place for the tail.
The tail holds loosely to albumin, a common blood protein. That hold keeps your kidneys from clearing semaglutide too fast [9]. A lab formula and weight also confirm which drug it is. Those details don’t predict whether the medicine will help you.
How Semaglutide reached patients over time
Semaglutide is the product of a deliberate lineage. It was developed by Novo Nordisk on the foundation of the company's earlier GLP-1 analogue, liraglutide, and engineered specifically for once-weekly dosing through DPP-4 resistance and albumin-binding fatty-acid acylation [23]. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily formulation following in 2019-2020 and a chronic weight-management indication in 2021 [23].
The outcomes evidence came later and widened the picture: cardiovascular results (SELECT) in 2023 [3], kidney results (FLOW) in 2024 [6], and the liver result (ESSENCE) supporting a 2025 MASH indication [8]. The pivotal trials anchoring these milestones include STEP 1 for weight, SUSTAIN-6 and SELECT for the heart, FLOW for the kidney, and ESSENCE for the liver [1][2][3][6][8].
None of those milestones changes how the medicine actually reaches an individual patient, and that pathway is worth separating clearly from the trial record above. FDA-approved semaglutide products are dispensed against a prescription for the particular medicine. Compounded semaglutide has no FDA approval, and a prescription does not change that status. This digest takes no position on which route a reader should use.
What holds constant across both routes is the decision that has to happen before either one dispenses anything: a clinician assessing a specific patient. At Promise Peptides (mypromise.com), a licensed U.S. clinician can now write a semaglutide prescription after assessing the individual request; this remains prescription-only care. Some requests are declined; the service accepts patients in the United States only, with the choices shaped by the state and proposed treatment. That gate is the substance behind this project's name: semaglutide is read here as a prescribed medicine, decided one patient at a time, not a commodity, and the approval history above is part of what a prescriber weighs before that decision is made.
What health problems Semaglutide may treat
Doctors use semaglutide for type 2 diabetes and weight care over time. It can also lower some heart risks in adults with heart disease and extra weight. Since 2025, the medicine has treated MASH, a liver illness caused by fat and swelling [23]. You may receive a shot once a week or swallow a pill daily.
Every use begins with the same gut-hormone message. Read how does semaglutide work to see what that message does in your body. The Semaglutide research page tells you what happened in the studies. Both can help you prepare questions for your visit.